Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma

Abstract

<jats:sec><jats:title>Aims</jats:title><jats:p>Triple-negative breast cancer comprises different histological subtypes, including metaplastic breast cancer (MBC) and ductal carcinomas (IDCs). The purpose of this study was to compare triple-negative MBC (TN-MBC) with triple-negative IDC (TN-IDC) in terms of survival and predictive factors.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>With access to the Surveillance, Epidemiology and End Result (SEER) database, a total of 19 383 patients met the eligibility criteria. Clinicopathological characteristics were compared between groups using the χ<jats:sup>2</jats:sup> test. Univariate and multivariate analyses were applied to evaluate the disease-specific survival (DSS) and overall survival (OS). Subgroup analyses summarised the hazard ratios of TN-MBC versus TN-IDC using a forest plot.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 586 patients with TN-MBC and 18 797 with TN-IDC were included in this study. Patients with TN-MBC were older and presented with larger tumour sizes, relatively rare lymph node positive disease, and had received more chemotherapy. Compared with TN-IDC, the TN-MBC group showed a significantly poorer prognosis before and after the 1:3 matched case-control analysis. Further subgroup analysis indicated that patients with TN-MBC were older, were from specific races, and those with distant metastasis and not receiving radiotherapy had worse prognosis than patients with TN-IDC in terms of DFS and OS.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Our results showed that patients with TN-MBC had unique clinicopathological characteristics and poorer prognostic subtype compared with TN-IDC. This improves our understanding of the clinicopathological and prognostic features of this rare entity but also provides more convincing therapeutic guidelines for TN-MBC in patients with breast cancer.</jats:p></jats:sec>

The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma

“…However, there were only 24 and 29 patients in the MBC groups in the aforementioned two studies respectively, which limited representation of the study participants to the entire population of MBC. In recent years, several population-based studies have indicated that there appears to be lower disease-specific survival in MBC patients compared to IDC patients [10][11][12] . In our study, we used a large cohort to compare the outcomes between MBC and IDC diagnosis, and our results are consistent with the findings from previous population-based studies [10][11][12] .…”

Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma

“…According to our review, its prognosis was worse not only when compared with conventional invasive ductal carcinomas, but also when compared with other TNBC. We reviewed 8 series comparing survival between patients with MBC and TNBC [ 21 , 22 , 24 , 25 , 26 , 62 , 63 , 64 ]. These series included a total of 2,007 MBC and 41,937 TNBC.…”

Marital Status and Survival in Osteosarcoma Patients: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

“…The Surveillance, Epidemiology, and End Results (SEER) database, funded by the National Cancer Institute (NCI), has been broadly applied in cancer research and used to explore developments in rare cancers, secondary malignancies, epidemiology, treatments, and outcomes [11,12]. The incidence, prevalence, and survival information on cancers in the database were collected from U.S. cancer registries, and the database has been utilized for thousands of studies, including those on colorectal cancer [13], non-small cell lung cancer [14], gastric cancer [15], and breast cancer [16]. Recently, it has been reported that marital status can independently predict the survival of patients with various cancers, such as colorectal cancer [17], gastric cancer [18,19], nasopharyngeal carcinoma [20], and liver cancer [21].…”